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ABSTRACT
Hypothyroidism affects up to 5% of the general
population, with a further estimated 5% being
undiagnosed. Over 99% of affected patients
suffer from primary hypothyroidism. World-
wide, environmental iodine deficiency is the
most common cause of all thyroid disorders,
including hypothyroidism, but in areas of
iodine sufficiency, Hashimoto’s disease (chronic
autoimmune thyroiditis) is the most common
cause of thyroid failure. Hypothyroidism is
diagnosed biochemically, being overt primary
hypothyroidism defined as serum thyroid-
stimulating hormone (TSH) concentrations
above and thyroxine concentrations below the
normal reference range. Symptoms of
hypothyroidism are non-specific and include
mild to moderate weight gain, fatigue, poor
concentration, depression, and menstrual
irregularities, while the consequences of
untreated or under-treated hypothyroidism
include cardiovascular disease and increased
mortality. Levothyroxine has long been the
main tool for treating hypothyroidism and is
one of the world’s most widely prescribed
medicines. In adults with overt hypothy-
roidism, levothyroxine is usually prescribed at a
starting dose of 1.6 lg/kg/day, which is then
titrated to achieve optimal TSH levels (0.4–4.0
mIU/L), according to the therapeutic target. We
here summarise the history of levothyroxine
and discuss future issues regarding the optimal
treatment of hypothyroidism. Because nearly
one-third of patients with treated hypothy-
roidism still exhibit symptoms, it is important
that levothyroxine is used more appropriately
to achieve maximum benefit for patients. In
order to ensure this, further research should
include more accurate assessments of the true
prevalence of hypothyroidism in the commu-
nity, optimisation of the levothyroxine substi-
tution dose, proper duration of treatment, and
identification of patients who may benefit from
combination therapy with levothyroxine plus
levotriiodothyronine.
Funding: Merck.
Plain Language Summary: Plain language
summary available for this article.
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.9705650.
L. Chiovato (&)  F. Magri
Istituti Clinici Scientifici Maugeri IRCCS, Unit of
Internal Medicine and Endocrinology and
Department of Internal Medicine and Therapeutics,
University of Pavia, Pavia, Italy
e-mail: luca.chiovato@icsmaugeri.it
A. Carlé
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PLAIN LANGUAGE SUMMARY
Hypothyroidism is one of the most common
diseases worldwide, and levothyroxine is the
usual medication prescribed to manage it.
Hypothyroidism occurs when the thyroid
gland, located in the neck, does not produce
enough thyroid hormone for the body’s
requirements. This can result in heart disease,
infertility, and poor brain development in
children. People with hypothyroidism may
have changes in body weight, and feel tired,
weak or unhappy, all of which can reduce their
quality of life. In underdeveloped parts of the
world, the main reason why people develop
hypothyroidism is that they not getting enough
iodine from food. Thus, many countries try to
increase iodine intake by adding iodine to salt.
In areas of the world where people ingest
enough iodine, the most common cause of
hypothyroidism is Hashimoto’s disease. This is
an autoimmune disease in which the person’s
immune system produces cells and antibodies
that attack the thyroid gland. Most people with
hypothyroidism will need to take levothyroxine
for a long time, perhaps even for the rest of their
lives. Levothyroxine replaces the person’s levels
of thyroid hormone and makes them feel better,
but the dose often needs to be adjusted for the
best effect. In addition, many people with
hypothyroidism do not know they have it.
Research is ongoing to ensure that more people
with hypothyroidism are diagnosed and are
given effective treatment, and to work out the
best way to use levothyroxine so that patients
get the best results.
INTRODUCTION
Hypothyroidism is a chronic disease associated
with deficiency in the thyroid hormones, thy-
roxine (T4) and triiodothyronine (T3) [1, 2]. The
consequences of untreated or inadequately
treated hypothyroidism include infertility,
cardiovascular disease, and neurological and
musculoskeletal symptoms [3–5]. Environmen-
tal iodine deficiency is the most common cause
of thyroid disorders, including hypothyroidism,
worldwide [6], while in areas of iodine suffi-
ciency, the most common cause of primary
hypothyroidism is autoimmune thyroiditis
(Hashimoto’s disease) [2, 6, 7].
The full implications of hypothyroidism in
the population are not completely appreciated
or defined. Hypothyroidism affects up to 5% of
the population according to European preva-
lence estimates [8–11], while as many as 5% of
the population may have undiagnosed thyroid
failure [9]. Of patients who are treated, up to
one-third are not receiving adequate treatment
[12, 13]. The economic impact of undiagnosed,
untreated or undertreated hypothyroidism is
therefore not inconsequential, especially with
regard to costs associated with maternal and
congenital hypothyroidism [14, 15], or with
hypothyroid patients having comorbid condi-
tions such as diabetes mellitus [16]. Hypothy-
roidism is also associated with decreased quality
of life [1, 12, 17–19], increased number of sick
leave days [20], and even increased mortality
[21].
Levothyroxine is the mainstay of treatment
for hypothyroidism, and is one of the World
Health Organization’s essential medicines
required for basic health care [22]. Here, we
review the background of hypothyroidism,
including aetiology, prevalence, and symptoms,
with a focus on the use of levothyroxine in the
management of hypothyroidism. In particular,
we review advances to date and unresolved
issues in the treatment of hypothyroidism.
METHODS
A search of the literature was conducted using
PubMed and general search terms such as pri-
mary hypothyroidism, levothyroxine, aetiol-
ogy, economic impact, quality of life and
treatment guidelines. Potential articles of
interest were identified by title and abstract, and
citation lists of articles of interest were used to
identify additional literature. This article is
based on previously conducted studies and does
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not contain any studies with animals performed
by any of the authors. Some of the cited studies
include analyses, or studies with human par-
ticipants, performed by the authors and com-
pleted prior to the initiation of this manuscript.
HYPOTHYROIDISM IN CONTEXT
Causes of Hypothyroidism
As described earlier, hypothyroidism is charac-
terised by deficiency in the T4 and T3 hormones
[1, 2]. T4 is the main hormone produced by the
thyroid gland, which only produces a small
amount of T3. Only 20% or less of T3 in
peripheral tissue originates in the thyroid gland
[23, 24]; the rest is derived from the enzymatic
conversion of T4 to T3 within the target tissues
[2]. Failure of the thyroid to produce T4 and T3
stimulates the pituitary to increase production
of a thyroid-stimulating hormone (TSH)
through a negative feedback mechanism [2].
In over 99% of cases, hypothyroidism is
caused by a failure of the thyroid gland to pro-
duce thyroid hormones (primary hypothy-
roidism) [2, 25]. The remaining 5% of patients
have hypothyroidism from other causes,
including secondary hypothyroidism, caused by
underproduction of TSH by the pituitary gland,
tertiary hypothyroidism, caused by deficiency
of thyrotropin-releasing hormone, and periph-
eral (extra-thyroidal) hypothyroidism [2, 3].
Central hypothyroidism, which includes both
secondary and tertiary hypothyroidism, and
peripheral hypothyroidism account for less
than\ 1% of cases [3, 26].
A large population study in Denmark repor-
ted that the most common subtype (present in
84.4% of patients) was spontaneous (presum-
ably autoimmune) hypothyroidism, followed
by post-partum (4.7%) and amiodarone-in-
duced hypothyroidism(4.0%). Less common
causes were subacute thyroiditis (1.8%), previ-
ous radiation or surgery (1.8%) to the thyroid
gland, congenital hypothyroidism (1.6%) and
lithium-associated (1.6%) thyroid failure [7].
Nowadays, iatrogenic causes have become more
frequent due to various immunotherapies.
Prevalence and Incidence
The reported prevalence of hypothyroidism
varies geographically, in part due to differences
in disease definitions, poorly defined and
diverse populations studied, variability in the
sensitivity of measures of thyroid function used
in the past, and iodine intake [27]. In Europe,
the estimated prevalence of overt (i.e. symp-
tomatic) hypothyroidism in the general popu-
lation is 0.2–5.3% [8–11, 28]. Across nine
European countries, the prevalence of undiag-
nosed hypothyroidism, including both overt
and subclinical hypothyroidism, has been esti-
mated at approximately 5% in a meta-analysis
of seven studies [9]; the same meta-analysis
calculated the incidence rate at 226.2
(222.26–230.17) per 100,000 per year. Similarly,
the prevalence of overt and subclinical
hypothyroidism in the US has been estimated at
0.3% and 4.3%, respectively [29].
Primary hypothyroidism is up to 8–9 times
more common in women than in men, and the
prevalence increases with age, with a peak
incidence between the ages of 30 and 50 years
[2, 30]. In the US, hypothyroidism affects an
estimated 4% of women aged 18–24 years and
21% of women older than 74 years [27];
respective values in men are 3% and 16% [27].
A UK survey determined that approximately
7.5% of women and 2.8% of men have elevated
serum levels of TSH [10], while a Danish popu-
lation study found that the lifetime risk of overt
hypothyroidism was 4.1% in women and 1.3%
in men [7].
Hypothyroidism also appears to be more
prevalent in white people than in black or His-
panic people [29–32].
Impact of Iodine
Worldwide, environmental iodine deficiency is
the most common cause of thyroid disorders,
including hypothyroidism [6]. Iodine is an
essential component of thyroid hormones, but
is also thought to make the thyroid gland more
antigenic [2, 3, 33]. Despite the implementation
of iodine supplementation programmes (e.g.
salt iodization), iodine intake remains
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suboptimal in large parts of Europe, Africa and
Asia [34], while it can affect specific subpopu-
lations in developed countries, such as pregnant
women in some areas of Italy, the US and UK
[3, 33–36]. Socioeconomic factors may play a
role in the lack of adherence to iodine supple-
mentation programmes. A recently published
Italian study showed that poverty and lack of
access to public health services were barriers to
the use of iodized salt and maternal iodine
supplements among poor or immigrant women
[37]. Iodine intake and hypothyroidism
demonstrate a ‘‘U-shaped’’ relationship:
hypothyroidism prevalence decreases in popu-
lations with mild iodine deficiency as compared
to those with severe deficiency, while autoim-
mune hypothyroidism increases in prevalence
as population iodine intake increases to suffi-
ciency or excess [3].
Autoimmune Hypothyroidism
In areas of iodine sufficiency, the most common
cause of primary hypothyroidism is chronic
autoimmune thyroiditis (Hashimoto’s disease)
[2, 6]. Hashimoto’s disease is characterised by
diffuse infiltration of the thyroid by lympho-
cytes and the presence of thyroid auto-anti-
bodies, such as anti-thyroid peroxidase (TPOAb)
and anti-thyroglobulin antibodies (TgAb)
[2, 38]. One study found that the prevalence of
overt hypothyroidism was strongly correlated
with the presence of the former, with no
hypothyroid individuals having positive TgAb
in the absence of positive TPOAb [29]. Thyroid
antibody positivity is almost universal ([95%)
among patients with overt hypothyroidism [39]
and present in * 50% with subclinical
hypothyroidism [40], while 10–20% of the
background population have thyroid antibodies
[41].
While this disease entity is often named
Hashimoto’s hypothyroidism, all cases in the
original study by Hashimoto had large goitres
[42]. Therefore, autoimmune hypothyroidism is
often referred to as Ord’s hypothyroidism in
those with small thyroid glands, and Hashimo-
to’s disease in those with goitres [43]. However,
this distinction is not clear-cut since thyroid
size in hypothyroidism shows a normal distri-
bution, with cases of thyroid atrophy or goitre
representing extremes within this distribution
[43].
The prevalence of autoimmune thyroiditis is
increased in populations with high dietary
iodine, as well as in severely iodine-deficient
populations, likely as a result of prolonged
thyroid adaptation to iodine intake in both
cases [2, 3, 44, 45]. Other environmental factors
that have been implicated in autoimmune
thyroiditis are deficiencies in vitamin D [46]
and selenium [47], whereas moderate alcohol
consumption has been found to reduce the risk
[48]. Immune changes during pregnancy can
also provoke the onset of autoimmune
hypothyroidism, which occurs at a rate of 92.3
per 100,000 women per year according to a
nationwide Danish study [49].
Primary hypothyroidism can also be caused
by damage to, or destruction of, the thyroid
gland caused by treatment or conditions, such
as thyroidectomy, radioactive iodine therapy
for Graves’ disease or nodular goitre, radio-
therapy for head and neck cancer, or toxic
exposure to some chemicals or drugs [2, 3].
Drugs that may cause hypothyroidism include
amiodarone, interleukin-2, kinase inhibitors,
and lithium [50]. Rarely, primary hypothy-
roidism may be congenital, caused by failed
embryologic development of the thyroid gland
(thyroid dysgenesis) or inherited defects of the
genes responsible for the thyroid hormone
synthesis (thyroid dyshormonogenesys) [3, 7].
Burden of Hypothyroidism
The economic impact of undiagnosed/un-
treated hypothyroidism may be significant,
especially with regard to costs associated with
maternal and congenital hypothyroidism
[14, 15], or with hypothyroid patients having
comorbid conditions such as diabetes mellitus
[16].
Hypothyroidism is also associated with
decreased quality of life, most likely related to
symptoms such as changes in body weight,
fatigue, weakness and depression [1, 12, 17–19].
Physicians and patients themselves rate fatigue
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and emotional susceptibility as being particu-
larly relevant to the impact of hypothyroidism
[51].
Hypothyroidism is implicated in many other
diseases, involving most organs of the body, but
is most extensively studied in terms of cardio-
vascular disease. Specifically, hypothyroidism is
associated with reduced cardiovascular con-
tractility, and its association with coronary
artery disease has long been recognised [3].
Hypothyroidism also contributes to infertility
[3, 4], and can cause reversible dementia, as well
as neurosensory, musculoskeletal and gastroin-
testinal symptoms [3]. A considerable number
of untreated patients with either overt or sub-
clinical hypothyroidism show evidence of
asymptomatic small fibre sensory neuropathy
[5].
Diagnosis of Hypothyroidism
Hypothyroidism has a varied clinical presenta-
tion and non-specific symptoms, including
weight gain, fatigue, poor concentration,
depression, diffuse muscle pain, menstrual
irregularities, and constipation [4], with no
particular symptom definitively predicting the
presence of hypothyroidism [52]. Furthermore,
symptoms generally become apparent by the
time (and even long-term after) circulating
thyroxine levels have decreased [53]. As a result,
patients with overt hypothyroidism exhibit a
greater number of symptoms [27], but only
some of them, such as constipation, dry skin,
hair loss and proximal weakness, are more
characteristic of thyroid failure [4]. While not
definitive, use of symptoms to diagnose
hypothyroidism is more successful in some
population groups than in others. Symptoms
more accurately predict overt hypothyroidism
in men than in women [54], and in younger
than older people, particularly in younger men
compared with older women [55].
The diagnosis of hypothyroidism is therefore
entirely based on repeated biochemical findings
[3, 4, 26, 53, 55, 56].
An imbalance between reactive oxygen spe-
cies and the anti-oxidant defence system, lead-
ing to an increased oxidative stress, has been
described in humans and in animal models of
hypothyroidism [57]. The pro-oxidant environ-
ment induced by hypothyroidism could pro-
mote the atherosclerotic processes frequently
described in this condition. In an experimental
model of hypothyroidism, the total nitric oxide
synthase (NOS) activity increased and signifi-
cant changes in the mRNA and protein expres-
sion of all three NOS isoforms were observed
[58]. However, serum assays of pro-oxidant and
anti-oxidant species are currently not included
in the diagnostic work-up of hypothyroid
patients.
Overt primary hypothyroidism is defined as
serum TSH concentrations above, and free thy-
roxine concentrations below, the normal refer-
ence range [3, 53]. It is also important to note
that reference ranges are a subject of ongoing
debate and differ with the assay used, as well as
by patient age, sex, and ethnic origin [3]. The
upper limit of the TSH reference range generally
increases with age in adults [3]. Furthermore,
individuals have their own TSH reference range,
which effectively covers only 25% of the refer-
ence range for the entire population [59].
LEVOTHYROXINE
Thyroid hormone replacement therapy with
levothyroxine, the exogenous form of T4, has
been the ‘‘gold standard’’ for the treatment of
primary hypothyroidism for more than 60 years
[60]. The first use of thyroid hormone to treat
hypothyroidism was documented in the 1890s,
when an ovine thyroid gland was grafted into a
patient with myxoedema (severe hypothy-
roidism) [61]. Subsequently, sheep thyroid
extract was injected into two patients with
myxoedema [61, 62], with both showing an
improvement in their condition. Extraction of
the vital ingredient, thyroxine, followed in
1914, with its structure finally established a
decade later [63, 64]. Synthetic formulations of
thyroxine have been available for use since the
1950s. However, desiccated animal thyroid
gland remained the mainstay of therapy until
the 1970s [63, 64].
Thyroxine occurs naturally as a racemic
mixture of levo (sodium L-thyroxine) and
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dextro forms [64]. Levothyroxine was intro-
duced in 1962 with the realization that the levo
form was better absorbed and had greater
physiological activity compared with the dextro
form [63, 64]. In the 1970s, it was also noted
that administration of both LT4 and LT3 was
not required for successful treatment of
hypothyroidism [65]. Because the T3 prepara-
tions have a short biological half-life, the
treatment approach transitioned to LT4
monotherapy, such that today almost all
patients with hypothyroidism receive once-
daily synthetic thyroxine preparations [4].
Levothyroxine is available as tablets and soft-
gel caps, intravenously, and, more recently, in
liquid formulations (Table 1) [60, 65]. The liq-
uid formulations demonstrate improved
absorption when ingested with food, and have
been developed with the aim of improving
adherence [1, 65].
Because levothyroxine is classified as a nar-
row therapeutic index medication, indicating
that small differences in dose or blood concen-
tration may lead to therapeutic failure or
adverse drug reactions [66], the American
Association of Clinical Endocrinologists, Amer-
ican Thyroid Association (ATA) and the Endo-
crine Society recommended the consistent use
of a single preparation of brand-name levothy-
roxine over generic preparations, which can
vary in potency (Table 1) [2, 60, 63, 67, 68].
Levothyroxine is among the most widely
prescribed medications in the world, and is one
of the two most frequently prescribed medica-
tions in the US [60, 69, 70]. It is considered by
the World Health Organization as an essential
medicine for basic health care [22].
THE USE OF LEVOTHYROXINE
TO TREAT HYPOTHYROIDISM
Upon diagnosis of hypothyroidism, lifelong
treatment with levothyroxine is often initiated
[4, 53, 67, 68, 71–73], except in cases where
hypothyroidism is caused by transient forms of
thyroiditis or by drugs which can be discontin-
ued [50].
The starting dose of levothyroxine depends
on patient age, the presence of co-existing
cardiac disease, and the aetiology and the
severity of the patient’s biochemical hypothy-
roidism [2]. The levothyroxine dose is titrated
until TSH levels are normalised [53, 71, 73] at
between 0.4 and 4.0 mIU/L [68]. Healthy adult
patients diagnosed with overt hypothyroidism
aged less than 50 years usually receive the full
replacement dose of levothyroxine (1.6 lg/
kg/day) orally, while those with coronary artery
disease or aged 50–60 years receive a lower
starting dose (25–50 lg once daily) [71]. In
pregnancy, dose adjustment of levothyroxine
should aim to achieve TSH in the lower half of
the trimester-specific range, when available, or
below 2.5 mIU/L [74]. In subclinical hypothy-
roidism, doses around 50–75 lg may be suffi-
cient for normalising the serum TSH.
Due to the long half-life of levothyroxine
(1 week), TSH should be measured 4–6 weeks
after initiation of therapy or dosage change.
Thereafter, patients with stable normal serum
TSH levels should be monitored every
12 months [67, 71, 73].
The goal of levothyroxine treatment is to
reduce symptoms and prevent long-term com-
plications [2, 53, 68, 71, 72]. Generally, disease
control is easily accomplished, with full recov-
ery upon adequate replacement of thyroid hor-
mones [2]. Over a period of years, levothyroxine
replacement dose may require adjustment as
the disease progresses or if the patient develops
other conditions that affect thyroid hormone
metabolism [2]. Other factors that can lead to,
or necessitate, an adjustment in levothyroxine
dose include a lack of medication adherence,
use of concomitant medications or dietary
supplements such as calcium or iron, and
changes in body mass and dietary habits [60].
UNRESOLVED ISSUES
IN HYPOTHYROIDISM
MANAGEMENT
Despite the switch to levothyroxine monother-
apy in the 1970s [65], the need for combination
therapy with levothyroxine ? LT3 has been
recently readdressed in several clinical guideli-
nes [13, 75, 76]. More than a third of patients
remain inadequately treated despite
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levothyroxine therapy, with evidently elevated
TSH levels and/or persistent symptoms [12, 13].
Even when TSH levels are controlled on
levothyroxine, about 5–10% of treated
hypothyroid patients have persistent symptoms
for various reasons [76], including differences in
individual set-points, coexistence of other
autoimmune diseases, and failure to appropri-
ately convert T4 to T3 with a low T3/T4 ratio,
on levothyroxine monotherapy.
It has been argued that, in such patients, the
addition of synthetic LT3 to standard LT4
therapy would create a more natural treatment
plan [13]. The majority of Clinical Guidelines
have addressed this issue and recommend
against the routine use of combination therapy,
but European, UK and ATA guidelines recom-
mend combination therapy as an individual
experimental approach, but only in some cir-
cumstances [13, 65, 68, 76]. The 2012 European
Thyroid Association guidelines only recom-
mend combination therapy as an experimental
approach in patients with ongoing symptoms
despite good adherence to LT4 therapy, and a
serum TSH within the normal reference range
for longer than 6 months [76]. The Italian
Society of Endocrinology and the Italian Thy-
roid Association endorsed this instance in a
2016 paper [77]. Prior to commencing com-
bined therapy, other autoimmune conditions
(e.g. type 1 diabetes mellitus, autoimmune B12
deficiency, adrenal insufficiency, coeliac dis-
ease) must be ruled out and, if symptoms do not
improve after 3 months, the patient should be
shifted back to T4 monotherapy [76].
Another matter of debate is the treatment of
subclinical hypothyroidism with levothyrox-
ine. While there is consensus on the need to
treat subclinical hypothyroidism with
levothyroxine in pregnant women and in those
contemplating pregnancy, in order to decrease
the risk of pregnancy complications and effects
on infant cognitive development, treatment of
non-pregnant adults remains controversial
[78]. Subclinical hypothyroidism is considered
a sign of early thyroid failure [3, 79–81] and is
defined as serum TSH concentrations above the
reference range associated with a normal con-
centrations of free thyroxine. However, there is
debate about which upper reference range of
serum TSH should be used as a threshold for
treatment [3, 80, 81]. It is believed that treat-
ment of subclinical hypothyroidism with
levothyroxine may prevent progression to
overt hypothyroidism, as well as reduce the
occurrence of coronary artery disease and
improve neuropsychiatric and musculoskeletal
symptoms associated with hypothyroidism
Table 1 Available formulations of levothyroxine
Product Manufacturer Initial AB,
subsequent
AB
AB rating
Tablets
Unithroid Stevens BX AB1, AB2,
AB3
Synthroid Abbvie BX AB1, AB2
Levoxyl King BX AB1, AB3
Levo-T Alara BX AB1, AB2,
AB3
LT4 Mylan BX AB1, AB2,
AB3,
AB4
Soft-gel caps
Tirosint IBSA None None
Intravenous
LT4 Fera pharm AP
LT4 Fresenius AP
LT4 Par sterile AP
Liquid
Tirosint-
SOL
IBSA
AB rating indicates interchangeability across formulations
where AB1 = therapeutic equivalence with Unithroid;
AB2 = therapeutic equivalence with Synthroid;
AB3 = therapeutic equivalence with Levoxyl;
AB4 = therapeutic equivalence with Levothroid (Thyro-
Tabs); and BX = data are insufficient to determine ther-
apeutic equivalence and therefore presumed non-equiva-
lent. AP rating also indicates clear in vivo and/or in vitro
evidence of equivalence for aqueous solutions
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[82, 83]. However, these benefits must be bal-
anced against the risk of cardiovascular, neu-
ropsychiatric and musculoskeletal side effects
associated with the administration not only of
excess levothyroxine but also of a normal
substitution dose [82]. Indeed, there is evi-
dence to suggest that, at least in very old
patients, subclinical hypothyroidism may
confer a longevity benefit over euthyroidism,
with patients with lower levels of circulating
T4 living longer [84]. Since there is currently a
lack of data regarding the benefits/risks of
treatment of subclinical hypothyroidism
[80, 81, 83, 85], the decision on whether or not
to treat should be individualised [79, 80].
Further studies are clearly warranted in the
areas of subclinical hypothyroidism and
regarding the use of levothyroxine monother-
apy versus combination therapy with LT3. The
rates of underdiagnosis and undertreatment of
hypothyroidism and the issue of iodine insuf-
ficiency must also be addressed. However, life-
long treatment with levothyroxine has
successfully treated many people with
hypothyroidism over the last 60 years, and will
continue to benefit many others in the future.
ACKNOWLEDGEMENTS
This supplement has been sponsored by Merck.
Funding. Sponsorship for this manuscript,
the Rapid Service and Open Access Fees were
funded by Merck.
Medical Writing, Editorial, and Other
Assistance. We would like to thank Andrea
Bothwell and Marion Barnett who drafted an
outline and early version of this manuscript on
behalf of Springer Healthcare. This medical
writing assistance was funded by Merck.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Disclosures. Luca Chiovato, Flavia Magri
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